{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:19:16Z","timestamp":1787170756655,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jid.2017.01.003","type":"journal-article","created":{"date-parts":[[2017,4,12]],"date-time":"2017-04-12T07:36:18Z","timestamp":1491982578000},"page":"1004-1008","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":78,"title":["Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology\u2014Thirty Years of Progress but Still Much to Be Done"],"prefix":"10.1016","volume":"137","author":[{"given":"Robert S.","family":"Stern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrie J.","family":"Divito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jid.2017.01.003_bib1","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3389\/fimmu.2015.00355","article-title":"IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells","volume":"6","author":"Ali","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.jid.2017.01.003_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib4","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/428486a","article-title":"A\u00a0marker for Stevens-Johnson syndrome","volume":"428","author":"Chung","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.jid.2017.01.003_bib5","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1038\/nm.1884","article-title":"Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"14","author":"Chung","year":"2008","journal-title":"Nat Med"},{"key":"10.1016\/j.jid.2017.01.003_bib6","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1182\/blood.V97.1.14","article-title":"Interleukin 15: biology and relevance to human disease","volume":"97","author":"Fehniger","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jid.2017.01.003_bib7","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1001\/archderm.136.3.323","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome. Does early withdrawal of causative drugs decrease the risk of death?","volume":"136","author":"Garcia-Doval","year":"2000","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib8","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/sj.jid.5700068","article-title":"Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis","volume":"126","author":"Guegan","year":"2006","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib9","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1001\/archderm.1987.01660330077013","article-title":"The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell\u2019s syndrome)","volume":"123","author":"Guillaume","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib10","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/bjd.13989","article-title":"Epidermal necrolysis: 60 years of errors and Advances","volume":"173","author":"Heng","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib11","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1038\/nri3919","article-title":"IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction","volume":"15","author":"Jabri","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.jid.2017.01.003_bib12","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.jaci.2011.08.013","article-title":"Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome","volume":"128","author":"Ko","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2017.01.003_bib13","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/sj.tpj.6500356","article-title":"A\u00a0marker for Stevens-Johnson syndrome\u2026. ethnicity matters","volume":"6","author":"Lonjou","year":"2006","journal-title":"Pharmacogenomics J"},{"key":"10.1016\/j.jid.2017.01.003_bib14","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.jid.5701033","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR study","volume":"128","author":"Mockenhaupt","year":"2008","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: a key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.jid.2017.01.003_bib16","doi-asserted-by":"crossref","first-page":"1027037","DOI":"10.1111\/cea.12145","article-title":"In\u00a0vitro drug causality assessment in Stevens-Johnson syndrome\u2014alternatives for lymphocyte transformation test","volume":"43","author":"Porebski","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jid.2017.01.003_bib17","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.immuni.2010.09.002","article-title":"The mammalian target of rapamycin: linking T cell differentiation, function, and metabolism","volume":"33","author":"Powell","year":"2010","journal-title":"Immunity"},{"key":"10.1016\/j.jid.2017.01.003_bib18","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1001\/archderm.1987.01660330071012","article-title":"Toxic epidermal necrolysis. Clinical findings and prognosis factors in 87 patients","volume":"123","author":"Revuz","year":"1987","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.1016\/j.jid.2017.01.003_bib20","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N\u00a0Engl J of Med"},{"key":"10.1016\/j.jid.2017.01.003_bib21","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/clpt.2009.252","article-title":"ALDEN, an algorithm for assessment of drug causality in Stevens-Johnson syndrome and toxic epidermal necrolysis: a comparison with case-control analysis","volume":"88","author":"Sassolas","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jid.2017.01.003_bib22","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.jid.2016.11.034","article-title":"Interleukin-15 is associated with severity and mortality in Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"137","author":"Su","year":"2017","journal-title":"J\u00a0Invest Dermatol"},{"key":"10.1016\/j.jid.2017.01.003_bib23","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1126\/science.282.5388.490","article-title":"Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin","volume":"282","author":"Viard","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.jid.2017.01.003_bib24","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1038\/jidsymp.2013.8","article-title":"The biology of IL-15: implications for cancer therapy and the treatment of autoimmune disorders","volume":"16","author":"Waldmann","year":"2013","journal-title":"J\u00a0Investig Dermatol Symp Proc"},{"key":"10.1016\/j.jid.2017.01.003_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1182\/blood-2012-08-450585","article-title":"Phase 1 trial of IL-15 trans-presentation blockade using humanized Mikbeta1 mAb in patients with T-cell large granular lymphocytic leukemia","volume":"121","author":"Waldmann","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jid.2017.01.003_bib26","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jaci.2015.05.050","article-title":"Evolving models of the immunopathogenesis of T cell-mediated drug allergy: the role of host, pathogens, and drug response","volume":"136","author":"White","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jid.2017.01.003_bib27","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomized comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"}],"container-title":["Journal of Investigative Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17300313?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022202X17300313?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T03:50:59Z","timestamp":1542945059000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022202X17300313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":27,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0022202X17300313"],"URL":"https:\/\/doi.org\/10.1016\/j.jid.2017.01.003","relation":{},"ISSN":["0022-202X"],"issn-type":[{"value":"0022-202X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Associations, Outcomes, and Pathobiology\u2014Thirty Years of Progress but Still Much to Be Done","name":"articletitle","label":"Article Title"},{"value":"Journal of Investigative Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2017.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jid.2016.11.034","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology.","name":"copyright","label":"Copyright"}]}}